Technical Analysis for RDHL - Redhill Biopharma Ltd.

Grade Last Price % Change Price Change
grade F 6.89 0.58% 0.04
RDHL closed up 0.58 percent on Friday, January 18, 2019, on 40 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical RDHL trend table...

Date Alert Name Type % Chg
Jan 18 Stochastic Sell Signal Bearish 0.00%
Jan 18 Hammer Candlestick Bullish 0.00%
Jan 18 Weak + Overbought Other 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 50 DMA Resistance Bearish 0.58%
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.58%
Jan 17 Weak + Overbought Other 0.58%
Jan 17 Outside Day Range Expansion 0.58%
Jan 17 Wide Bands Range Expansion 0.58%

Older signals for RDHL ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
RedHill Biopharma Ltd., a biopharmaceutical company, engages in the acquisition and development of patent-protected new formulations and combinations of existing drugs in advanced stages of development. The company's pipeline includes six clinical stage therapeutic candidates comprising RHB-101, a once daily controlled release patented formulation of Carvedilol for the treatment of hypertension, heart failure, and left ventricular dysfunction; RHB-102, a once daily controlled release oral formulation of Ondansetron for the prevention of nausea and vomiting for oncology-support treatments; and RHB-103, a proprietary oral fast dissolving thin film formulation of rizatriptan for the treatment of acute migraine headaches. Its pipeline also consists of RHB-104, a patented antibiotics drug for the treatment of inflammatory bowel disease focused on Crohn's disease patients; RHB-105, an antibiotics and proton pump inhibitor proprietary drug targeting helicobacter pylori infection; and RHB-106, a patented formulation in tablet form for the preparation and cleansing of the gastrointestinal tract. RedHill Biopharma Ltd. was founded in 2009 and is based in Tel Aviv, Israel.
Is RDHL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 11.49
52 Week Low 4.4
Average Volume 131,092
200-Day Moving Average 7.3762
50-Day Moving Average 7.1122
20-Day Moving Average 6.271
10-Day Moving Average 6.882
Average True Range 0.4188
ADX 21.15
+DI 23.3261
-DI 16.4614
Chandelier Exit (Long, 3 ATRs ) 5.9236
Chandelier Exit (Short, 3 ATRs ) 6.3864
Upper Bollinger Band 7.6407
Lower Bollinger Band 4.9013
Percent B (%b) 0.73
BandWidth 43.683623
MACD Line 0.0424
MACD Signal Line -0.0914
MACD Histogram 0.1338
Fundamentals Value
Market Cap 118.25 Million
Num Shares 17.2 Million
EPS -2.46
Price-to-Earnings (P/E) Ratio -2.80
Price-to-Sales 264.36
Price-to-Book 3.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.31
Resistance 3 (R3) 7.28 7.11 7.24
Resistance 2 (R2) 7.11 7.00 7.13 7.22
Resistance 1 (R1) 7.00 6.94 6.92 7.03 7.19
Pivot Point 6.83 6.83 6.79 6.85 6.83
Support 1 (S1) 6.72 6.72 6.64 6.75 6.59
Support 2 (S2) 6.55 6.66 6.57 6.56
Support 3 (S3) 6.44 6.55 6.54
Support 4 (S4) 6.47